NewAmsterdam Pharma Company N.V.
Status: Publicly traded
Direct answer
NewAmsterdam Pharma Company N.V. is publicly traded on NASDAQ under the ticker NAMS.
NewAmsterdam Pharma Company N.V. functions as a clinical-phase biopharmaceutical enterprise, dedicated to enhancing treatment outcomes for patients dealing with metabolic disorders. The company's principal experimental medication, obicetrapib, represents a pioneering and targeted inhibitor that acts on the Cholesteryl Ester Transfer Protein (CETP). This compound has demonstrated in clinical studies its capacity to...
Can you invest in NewAmsterdam Pharma Company N.V.?
Yes. NewAmsterdam Pharma Company N.V. is publicly traded on NASDAQ under the ticker NAMS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for NewAmsterdam Pharma Company N.V.
Detailed equity research is provided by MarketSnap.